Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system

Current Diabetes Reviews

Volumn 5, Issue 3, 2009, Pages 157-164

  Rosak, Christoph ^a   Mertes, Gabriele ^b  

^a Sachsenhausen Hospital   (Germany)

^b NONE   (Germany)

Author keywords

cell function; Acarbose; Cardiovascular disease; Proinsulin; Serum insulin

Indexed keywords

ACARBOSE; C PEPTIDE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROINSULIN; REPAGLINIDE; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT;

BODY WEIGHT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONCENTRATION RESPONSE; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERPROINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; HYPERINSULINISM; MORTALITY; SECRETION;

ACARBOSE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; PROINSULIN; RISK FACTORS;

EID: 70349784729     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909788920910     Document Type: Review

References (105)

1. King H, Aubert RE, Hermann WH. Global burden of Diabetes, 1995-2025, prevalence, numerical estimates and projections. Diabetes Care 1995; 21: 1414-1431
2. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Diabetes Care 2005; 28: 1588-1593
3. Köster L, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus-the CoDiM study. Diabetologia 2006; 49: 1498-1504
4. International Diabetes Federation (IDF). Diabetes Atlas. Available at: www.eatlas.idf.org [accessed March 2008]
5. Gaede P, Vedel P, Larsen N, Jensen GVH, Paving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-392 (Pubitemid 36159355)
6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580-591 (Pubitemid 351214285)
7. Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-145 (Pubitemid 28554677)
8. Laube H. Acarbose-an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22: 141-156 (Pubitemid 34275772)
9. Laar van de FA, Lucassen PL, Akkermans RP, Lisdonk van de EH, Rutten GE, Weel van C. Alpha-glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 2005; 28: 154-163
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486-494 (Pubitemid 37430502)
11. Given BD, Cohen RM, Shoelson SE, Frank BH, Rubenstein AH, Tager HS. Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest 1985; 76: 1398-1405
12. Pfützner A, Frost T. Intaktes Proinsulin als kardiovaskulärer Risikofaktor und prädikativer diagnostischer Marker für die Insulinresistenz bei Patienten mit Diabetes mellitus Typ 2 (In German). Diab Stoffwechsel 2004; 13: 193-197
13. Roder ME, Porte D Jr, Schwatz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with NIDDM. J Clin Endocrinol Metab 1998; 83: 604-608
14. Pfützner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004; 27: 682-687 (Pubitemid 38280533)
15. Haffner SM, Gonzalez C, Mykkänen L, Stern M. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 1997; 40: 830-837 (Pubitemid 27306962)
16. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14(Suppl 3): S6-11.
17. Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type 1 by proinsulin. Diabetologia 2001; 9: 1121-1124
18. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow up study. Circulation 2002; 105: 2153-2158 (Pubitemid 34517158)
19. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 326: 681-683 (Pubitemid 36390446)
20. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia 2005; 48: 862-867
21. Alessema M, Dekker JM, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality. Diabetes Care 2005; 28: 860-865
22. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG. Concentration of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002; 45: 327-336 (Pubitemid 34267354)
23. Yudkin JS. Increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes. Circulation 2002; 106: e202.
24. Eschwege E, Riehard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, 10 years later. Horm Metab Res Suppl 1985; 15: 41-46
25. Desprès JP, Lamarche B, Mauriè P, Cantini B, Degenais DR, Moorjani S. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957 (Pubitemid 26114161)
26. Pyorälä M, Miettinen H, Laakso M, Pyorälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98: 398-404. (Pubitemid 28357941)
27. Bonora E, Willeit J, Kiechl S, et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. Diabetes Care 1998; 21: 221-230 (Pubitemid 28079428)
28. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a metaanalysis. Circulation 1998; 97: 996-1001. (Pubitemid 28125472)
29. The DECODE Study Group. Prediction of cardiovascular mortality using a score that includes glucose as a risk factor. The Decode Study. Diabetologia 2004; 47: 2118-2128
30. Baltali M, Korkmaz ME, Kiziltan T, Muderris H, Ozin B, Anarat R. Association between postprandial hyperinsulinemia and coronary artery disease among non-diabetic women: a case control study. Int J Cardiol 2003; 88: 215-221 (Pubitemid 36513659)
31. Hirai FE, Moss SE, Klein BEK, Klien R. Relationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes. Diabetes Care 2008; 31(3): 493-497
32. Steiner G. Hyperinsulinemia and hypertriglyceridemia. J Int Med 1994; 236: 23-26
33. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1988; 37: 1-9.
34. Niskanen LK, Uusitupa MI, Pyorälä K. The relationship of hyperinsulinemia to the development of hypertension in Type 2 diabetic patients and in non-diabetic subjects. J Hum Hypertens 1991; 5: 155-159
35. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of postprandial hyperglycemia. Am Heart J 2004; 147: 803-807 (Pubitemid 38880985)
36. Ceriello A, Davidson J, Hanefeld M, et al. Postprandial hyperglycemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006; 16: 453-456 (Pubitemid 44466389)
37. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Arch Int Med 2001; 161: 397-405.
38. Saydah SH, Miret M, Sung J, Varas C, Gause D, Bromcati FL. Postchallenge hyperglycemia and mortality in a national sample of US adults. Diabetes Care 2001; 24: 1397-1402 (Pubitemid 33716427)
39. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulphonylurea therapy on plasma insulin, intact proinsulin and 32/33 split proinsulin in subjects with diabetes mellitus. Diabet Med 1994; 11: 293-298 (Pubitemid 24144146)
40. Hillebrand I, Boehme K, Frank G, Fink H, Berchhold P. Effect of the glucosidase inhibitor acarbose on postprandial blood glucose, serum insulin and triglyceride levels in normal and overweight subjects. In: Creutzfeldt W Ed, Proceedings of the First International Symposium on Acarbose. Amsterdam, Excerpta Medica 1982; 191-194
41. Hillebrand I, Boehme K, Frank G, Fink H, Berchhold P. Effect of the glucosidase inhibitor acarbose on postprandial blood glucose, serum insulin and triglyceride levels: dose-time relationship in man. In: Creutzfeldt W Ed, Proceedings of the First International Symposium on Acarbose. Amsterdam, Excerpta Medica 1982; 195-198
42. Puls W. Pharmacology of glucosidase inhibitors. In: Kuhlmann J, Puls W Ed, Handbook of Experimental Pharmacology: Oral Antidiabetics, Berlin, Springer 1996, Vol.119, 497-534.
43. Wachters-Hagedoorn RE, Priebe MG, Heimweg JAJ, et al. Low-dose acarbose does not delay digestion of starch but reduces its bioavailability. Diabet Med 2007; 24: 600-606
44. Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55. (Pubitemid 28394284)
45. Laar van de FA, Lucassen PI, Lisdonk van de EH, et al. How effective is acarbose in the treatment of type 2 diabetes mellitus? A Cochrane review. Diabetes Metab 2003; 29: 4S264.
46. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-1167 (Pubitemid 30616806)
47. Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1997; 36: 143-151 (Pubitemid 27306817)
48. Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 2002; 55: 221-227 (Pubitemid 34163293)
49. Rosak C, Hofmann U, Paulwitz O. Modification of B-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004; 17: 137-142 (Pubitemid 39117273)
50. Wagner H, Degerbald M, Thorell A, et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 2006; 29: 1471-1477 (Pubitemid 44127566)
51. Laube H, Linn TH, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106: 231-233 (Pubitemid 28356616)
52. Shinoda Y, Inoue I, Nakano T, et al. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism 2006; 55: 935-939 (Pubitemid 43902896)
53. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetes patients. Diabetes Metab 2002; 28: 195-200. (Pubitemid 34746953)
54. Wolever TMS, Singer W, Chiasson JL, Palmason C. Acarbose improves abnormal insulin metabolism in type 2 diabetes. Clin Res 1993; 41: 360A.
55. Iwase M, Iida M. Acarbose-feeding increases pancreatic islet blood flow in obese glucose-intolerant OLETF rats. Diabetes 2008; 57(Suppl 1): A412.
56. Bischoff H, Hartmann B, Stelte-Ludwig B, Zaiss S. Acarbose slows the progression of diabetes in Goto-Kakizaki rats due to diminished loss of pancreatic beta-cell mass. Diabet Med 2006; 23(Suppl 4): 806.
57. Yamamoto M, Otsuki M. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats. Metabolism 2006; 55: 533-540
58. Fischer S, Neumann S, Lindner J, et al. Diabeteseinstellung bei ehemaligen Teilnehmern von Acarbosestudien: Ergebnisse einer Langzeitbeobachtung. Diab Stoffwechsel (In German)1998; 7: 238-244 (Pubitemid 28550561)
59. Holmann RR, Turner RC, Cull CA, on behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in Type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 1999; 22: 960-964
60. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204. (Pubitemid 32385332)
61. Haffner SM, Hanefeld M, Fischer S, Fücker K, Leonhardt W. Glibenclamide but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997; 20: 1430-1434 (Pubitemid 27366820)
62. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17: 561-566 (Pubitemid 24161978)
63. Kovacevic I, Profocic V, Škrabalo Z, et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose in comparison to glibenclamide and placebo. Diabetol Croat 1997; 26: 83-89 (Pubitemid 27423881)
64. Salman S, Salman F, Satman I, et al. Comparison of acarbose and glyburide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 2001; 16: 296-306. (Pubitemid 32221487)
65. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glimepiride on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab 2002; 15: 143-151 (Pubitemid 34823242)
66. Rosak C. The use of acarbose as combination therapy for type 2 diabetics. Diabetes Metabetes Heart 2007; 16: 119-126
67. Kelly DE, Bidot P, Freedman Z. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2056-2061 (Pubitemid 28549151)
68. Güvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999; 36: 93-99
69. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulphonylurea treated NIDDM patients. Diabetes Care 1996; 19: 252-254 (Pubitemid 26070353)
70. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide-plus-acarbose in NIDDM. Am J Med 1995; 98: 443-451
71. Ko GTC, Tsang CC, Ng CW, Wai HPS, Kan ECY. Use of acarbose or bedtime insulin after failure of treatment with conventional oral antidiabetics, a one-year randomised clinical trial. Clin Drug Invest 200; 21: 401-408
72. Hwu CM, Ho LT, Fuh MMT, et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: Results from a multinational, placebo-controlled study. Diabetes Res Clin Pract 2003; 60: 111-118 (Pubitemid 36434262)
73. Lam KSL, Tiu SC, Tsang MW, Ip TP, Tam SCF. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care 1998; 21: 1154-1158
74. Schnell O, Mertes G, Standl E, on behalf of the Acarbose-Insulin Combination Study-Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9: 853-858
75. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56. (Pubitemid 30629019)
76. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179-185
77. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight Type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273 (Pubitemid 36929042)
78. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with Type 2 diabetes. Diabetes Care 1998; 21: 2050-2055 (Pubitemid 28549150)
79. Sumual AR, Pandelaki K, Rotty LAW. Acarbose-Metformin combination versus metformin alone. J Asian Fed Endocr Soc 2003; 21: 24-31.
80. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077 (Pubitemid 34680970)
81. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
82. Holman R, Blackwell L, Manley S, Tucker L, Frighi V, Stratton I. Results from the Early Diabetes Intervention Trial. Diabetes 2003; 52 (Suppl 1): A16.
83. Wolever TMS, Chiasson JL, Josse RG. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997; 21: 756-763
84. Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755-761 (Pubitemid 29459274)
85. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-490 (Pubitemid 28018650)
86. Laar van de FA. Diet and alpha-glucosidase inhibition in the early treatment of Type 2 diabetes mellitus, Nijmegen, Drukkerij Quickprint 2008; Chapter 6.
87. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441
88. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with NIDDM. Ann Intern Med 1994; 121: 928-935
89. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with NIDDM: a controlled double-blind comparison study with placebo. Diabetes Metab 1996; 22: 201-202 (Pubitemid 26193998)
90. Rachmani R, Bar-Dayan Y, Ronen Z, Levi Z, Slavachevsky I, Ravid M. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized, controlled study. Diabetes Obes Metab 2004; 6: 63-68 (Pubitemid 38159731)
91. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-1193 (Pubitemid 26363430)
92. Kahn SE, Leonetti D, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Relationship of proinsulin and insulin with non-insulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity: Clinical Research Centre Study. J Clin Endocrinol Metab 1995; 80: 1399-1406
93. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Werme D. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 1996; 45: 736-741
94. Haffner SM, Hanley AJG. Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation 2002; 105: 2008-2009
95. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-473 (Pubitemid 26093875)
96. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose. Diabetes 2004; 53(Suppl 2): A189.
97. Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerant subjects and the change in serum CRP level in IGT subjects with acarbose. Chin J Endocrinol Metab 2003; 19: 254-256
98. Rudofski G, Reismann P, Schiekofer S. Reduction of postprandial hyperglycemia in patients with Type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004; 36: 630-638 (Pubitemid 39457641)
99. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002; 22: 695-701. (Pubitemid 35155504)
100. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002; 106: 1211-1218
101. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 2005; 81: 1-6. (Pubitemid 40187130)
102. Baron AD, Eckel RH, Schmeiser L, Kolterman OG. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II diabetics. Metabolism 1987; 36: 409-415 (Pubitemid 17072104)
103. Malaguarnera M, Giugno I, Ruello P, Rizzo M, Motto M, Mazzoleni G. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias. Br J Clin Pharmacol 1999; 48: 605-609 (Pubitemid 29454242)
104. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab 2004; 6: 384-390 (Pubitemid 39177431)
105. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16 (Pubitemid 38055587)